TLR2 and breast carcinoma: As reported in previous studies, the CRD of SP-D can interact with pattern recognition receptors TLR-2, TLR-4 (50), and CD14 (22), which may block pro-inflammatory and pro-survival downstream signaling on breast cancer cells.